Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchAlkalinizationAlkalinization (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Alkalinization for COVID-19: real-time meta analysis of 14 studies

@CovidAnalysis, April 2024, Version 13V13
Post
Share
PDF
Studies
Feedback
https://c19early.org/phmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Yilmaz (SB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Improvement, RR [CI] Treatment Control Yilmaz (SB RCT) 62% 0.4 [0.00-2e+04] viral load 30 (n) 30 (n) Yilmaz (SB RCT) 43% 0.6 [0.00-2e+06] viral load 30 (n) 30 (n) Baxter (RCT) 65% 0.35 [0.01-8.27] hosp. 0/37 1/42 OT​1​ SeaCare de Gabory (RCT) 75% 0.25 [0.12-0.54] progression 7/82 31/91 SeaCare de Gabory (RCT) 68% 0.32 [0.15-0.71] progression 7/82 24/91 SeaCare de Gabory (RCT) 35% 0.65 [0.27-1.57] progression 7/82 12/91 SeaCare de Gabory (RCT) 24% 0.76 [0.60-0.96] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 17% 0.83 [0.76-0.91] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 26% 0.74 [0.57-0.97] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 29% 0.71 [0.57-0.87] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 26% 0.74 [0.61-0.92] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 14% 0.86 [0.68-1.09] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 11% 0.89 [0.70-1.13] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) -2% 1.02 [0.80-1.29] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 25% 0.75 [0.56-0.99] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 3% 0.97 [0.77-1.21] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 14% 0.86 [0.68-1.09] recov. time 82 (n) 91 (n) SeaCare de Gabory (RCT) 37% 0.63 [0.19-2.09] viral+ 4/82 7/91 Mody (RCT) 64% 0.36 [0.19-0.68] no improv. 8/30 22/30 Salva 45% 0.55 [0.35-0.85] death 35/327 34/174 CT​2​ Salva 76% 0.24 [0.14-0.43] death 11/56 17/21 CT​2​ Salva 14% 0.86 [0.83-0.90] hosp. time 327 (n) 174 (n) CT​2​ Salva 18% 0.82 [0.74-0.91] hosp. time 56 (n) 21 (n) CT​2​ Soares (ICU) 76% 0.24 [0.11-0.54] death 6/44 18/32 ICU patients Delić (RCT) 20% 0.80 [0.54-1.18] death 20/42 31/52 Intubated patients Calonico 49% 0.51 [0.31-0.85] death 1,019 (n) 3,303 (n) CT​2​ El-Badrawy 57% 0.43 [0.09-2.08] death 3/127 3/55 El-Badrawy 39% 0.61 [0.20-1.83] progression 7/127 5/55 El-Badrawy 19% 0.81 [0.68-0.96] no recov. 84/127 45/55 El-Badrawy 73% 0.27 [0.14-0.52] no recov. 127 (n) 55 (n) El-Badrawy 66% 0.34 [0.25-0.47] recov. time 127 (n) 55 (n) El-Badrawy (RCT) 23% 0.77 [0.50-1.18] death 32/272 42/274 El-Badrawy (RCT) 55% 0.45 [0.23-0.87] death 12/247 27/251 El-Badrawy (RCT) 79% 0.21 [0.02-1.76] death 1/125 5/130 El-Badrawy (RCT) 53% 0.47 [0.25-0.88] death 11/63 22/59 El-Badrawy (RCT) -23% 1.23 [0.86-1.75] death 20/25 15/23 El-Badrawy (RCT) 28% 0.72 [0.66-0.80] recov. time 272 (n) 274 (n) El-Badrawy (RCT) 33% 0.67 [0.52-0.85] no recov. 238 (n) 229 (n) Kalayan 79% 0.21 [0.07-0.65] death 3/37 24/62 CT​2​ Wang (RCT) 39% 0.61 [0.46-0.82] hosp. time 23 (n) 32 (n) Pantazop.. (SB RCT) 67% 0.33 [0.01-7.85] death 0/28 1/28 Pantazop.. (SB RCT) 67% 0.33 [0.01-7.85] ICU 0/28 1/28 Pantazop.. (SB RCT) 80% 0.20 [0.01-3.99] oxygen 0/28 2/28 Pantazop.. (SB RCT) 42% 0.58 [0.34-0.98] viral+ 11/28 19/28 Karami (DB RCT) 45% 0.55 [0.24-1.22] symptoms 40 (n) 40 (n) Karami (DB RCT) 43% 0.57 [0.17-1.99] symptoms 36 (n) 40 (n) Karami (DB RCT) 42% 0.58 [0.22-1.51] symptoms 36 (n) 40 (n) Karami (DB RCT) 79% 0.21 [0.04-0.97] symptoms 36 (n) 40 (n) Karami (DB RCT) 18% 0.82 [0.22-2.96] symptoms 36 (n) 40 (n) Karami (DB RCT) 39% 0.61 [0.33-1.12] cases 11/40 18/40 Alkalinization COVID-19 outcomes c19early.org April 2024 ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors alkalinization Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0